The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split and blister even with ...

Mía had dystrophic epidermolysis bullosa, better known as butterfly skin due to the extreme fragility of this tissue in people with this rare and serious genetic disease that prevents the body from ...

Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation. Read why KRYS ...

Krystal, which won U.S. Food and Drug Administration approval of Vyjuvek in 2023, recorded $290.5 million in net product revenue for the drug last year. Write to Colin Kellaher at colin.kellaher@ ...

In 2023, Krystal Biotech received FDA approval for Vyjuvek as the first-ever revocable gene therapy for treating patients ...

Nonetheless, shares surged post the quarterly release, mostly due to the strong uptake of Vyjuvek and encouraging pipeline progress. In May 2023, the FDA approved Vyjuvek, the first-ever revocable ...